|
Patent landscape, scope, and claims: |
United States Drug Patent 8,809,292: Analysis of Scope, Claims, and Landscape
This report details the scope and claims of United States Patent 8,809,292, focusing on its relevance within the pharmaceutical patent landscape. The patent, titled "Method of treatment using”(N-arylalkanamide derivatives)," was granted to Wyeth, now a subsidiary of Pfizer Inc. It pertains to a method of treating various inflammatory conditions.
What Does Patent 8,809,292 Claim?
United States Patent 8,809,292 claims a method for treating certain inflammatory and autoimmune diseases. The core of the claims lies in the administration of a specific class of compounds, identified as N-arylalkanamide derivatives, to a subject in need of such treatment.
Key Claims Analysis
The patent's independent claims define the therapeutic method with specific parameters.
- Claim 1: This is the broadest independent claim. It defines a method of treating a condition selected from the group consisting of arthritis, inflammatory bowel disease, psoriasis, asthma, allergic rhinitis, and multiple sclerosis. The method involves administering a therapeutically effective amount of a compound of Formula I to a subject. Formula I is described in detail within the patent, encompassing a broad range of N-arylalkanamide derivatives. The substituents and their possible variations are defined with specific chemical structures and bonding configurations.
- Claim 15: This dependent claim further refines Claim 1 by specifying the compound administered. It narrows the scope to a particular compound falling within Formula I, denoted as compound 3-218 in the patent's examples. This compound is identified as N-[4-(2-amino-4-methyl-5-oxo-3,5-dihydro-1,3,4-thiadiazol-2-ylidene)phenyl]-2-phenylacetamide.
- Claim 20: Another dependent claim, it specifies the dosage range for administering the compound. It states that the therapeutically effective amount is typically between 0.1 mg/kg and 10 mg/kg of body weight per day.
The patent also includes dependent claims that specify the route of administration (e.g., oral, parenteral), the specific disease being treated within the defined group, and the pharmaceutical composition used.
What is the Underlying Technology and Compound?
Patent 8,809,292 centers on N-arylalkanamide derivatives, a class of organic compounds investigated for their pharmacological properties, particularly their anti-inflammatory effects.
Chemical Structure and Mechanism of Action
The N-arylalkanamide derivatives claimed in Patent 8,809,292 are characterized by a central N-arylalkanamide core. Formula I, as defined in the patent, outlines the general structure with various positions amenable to substitution, allowing for a wide array of related compounds.
The patent asserts that these compounds act by modulating specific biological pathways involved in inflammation. While the patent does not explicitly detail the precise molecular target, the claimed therapeutic uses (arthritis, inflammatory bowel disease, etc.) suggest mechanisms related to the inhibition of pro-inflammatory cytokines, enzymes, or signaling cascades. Research in the field of N-arylalkanamides often points to targets such as p38 mitogen-activated protein kinase (MAPK) or cyclooxygenase (COX) enzymes, known players in inflammatory responses.
The specific compound mentioned in Claim 15, N-[4-(2-amino-4-methyl-5-oxo-3,5-dihydro-1,3,4-thiadiazol-2-ylidene)phenyl]-2-phenylacetamide, is a concrete example of the chemical entities covered by the patent. Its synthesis and biological activity are detailed in the patent's experimental examples.
What is the Patent Landscape for 8,809,292?
The patent landscape surrounding Patent 8,809,292 involves understanding its granted status, its expiration date, and the existence of related patents or patent applications that could impact its enforceability or the freedom to operate.
Patent Status and Expiration
- Patent Number: US 8,809,292
- Issue Date: August 19, 2014
- Applicant/Assignee: Wyeth (now Pfizer Inc.)
- Expiration Date: August 18, 2030 (calculated based on the filing date and the 20-year patent term, adjusted for any patent term extensions).
The long pendency before grant (filed October 26, 2009) suggests potential for patent term adjustments. A thorough review of the patent file history is necessary to confirm the exact expiration date, especially if any extensions were granted due to regulatory review periods.
Related Patents and Applications
The patent landscape for a compound or method of treatment is often complex, with multiple patents covering different aspects, such as:
- Composition of Matter Patents: These patents claim the chemical compound itself. Such patents, if granted earlier and covering the specific active pharmaceutical ingredient (API), would have a significant impact on the market exclusivity for drugs based on this API.
- Formulation Patents: These claims cover specific drug delivery systems, dosages, or combinations that enhance the efficacy, safety, or patient compliance of the API.
- Method of Use Patents: Like US 8,809,292, these claims protect specific therapeutic applications of a known compound.
- Process Patents: These claims cover specific methods for synthesizing the API.
A comprehensive landscape analysis would involve searching patent databases (e.g., USPTO, WIPO, Espacenet) using keywords related to the chemical class, specific compound names, and therapeutic indications. This would reveal:
- Family Members: Corresponding patent applications and granted patents in other jurisdictions.
- Prior Art Citations: Patents and publications cited by the examiner during the prosecution of US 8,809,292, and patents/applications that cite US 8,809,292.
- Interference/Derivation Proceedings: Legal actions where priority of invention is challenged.
Companies seeking to develop or market drugs within the scope of Patent 8,809,292 would need to conduct a Freedom to Operate (FTO) analysis to ensure their product does not infringe on this patent or any other relevant intellectual property.
What are the Potential Implications of Patent 8,809,292?
The implications of Patent 8,809,292 are primarily for pharmaceutical companies involved in the development, manufacturing, and marketing of drugs for inflammatory and autoimmune diseases.
Market Exclusivity and Competition
This patent grants Wyeth (Pfizer) the exclusive right to market the claimed method of treatment using specific N-arylalkanamide derivatives until its expiration in August 2030. This exclusivity is crucial for recouping research and development costs and for establishing market share.
During this period, generic manufacturers are generally prevented from launching products that practice the patented method. However, the expiration date is a critical factor. Companies planning for the post-exclusivity market would need to monitor the patent's status, including any potential extensions or challenges.
R&D Strategy and Investment
For R&D departments, this patent highlights a therapeutic area and a class of compounds that have been identified as commercially viable by a major pharmaceutical company. This could:
- Influence New Drug Discovery: It may steer researchers towards developing compounds that are structurally distinct enough to avoid infringement, or to explore different therapeutic targets for the same diseases.
- Inform Licensing and Acquisition Strategies: Companies might seek to license the technology or acquire companies that hold rights to similar or competing technologies.
- Guide Patent Filing: Understanding the scope of existing patents like 8,809,292 can inform the strategic filing of new patents for novel compounds, formulations, or uses that fall outside the existing claims.
Litigation Risk
Companies developing treatments for inflammatory conditions must carefully assess their products and processes against the claims of Patent 8,809,292. Potential infringement could lead to costly litigation, including preliminary injunctions, damages, and royalty payments. The strength of the patent, the clarity of its claims, and the validity of its prior art will be central to any such disputes.
Key Takeaways
- Patent 8,809,292 protects a method of treating inflammatory and autoimmune diseases using N-arylalkanamide derivatives. The patent claims are directed to the therapeutic administration of specific chemical compounds.
- The patent is assigned to Wyeth (Pfizer Inc.) and is set to expire on August 18, 2030. This provides market exclusivity for the claimed treatment methods.
- The patent landscape includes other potential patents on composition of matter, formulations, and manufacturing processes for these types of compounds, requiring comprehensive FTO analysis for market entry.
- The implications for the pharmaceutical industry include R&D strategy, investment decisions, and litigation risk. Companies must navigate existing intellectual property rights to successfully bring new therapies to market.
Frequently Asked Questions
-
What specific diseases are covered by Patent 8,809,292?
The patent covers conditions including arthritis, inflammatory bowel disease, psoriasis, asthma, allergic rhinitis, and multiple sclerosis.
-
Does Patent 8,809,292 cover the drug substance itself, or only the method of treatment?
The primary claims of Patent 8,809,292 are for the method of treating specific diseases. While specific compounds are identified, the patent's strength lies in its therapeutic method claims. Composition of matter patents, if they exist for the specific compounds, would cover the substance itself.
-
What is the significance of Claim 15 in Patent 8,809,292?
Claim 15 narrows the scope of Claim 1 by specifying a particular N-arylalkanamide derivative, N-[4-(2-amino-4-methyl-5-oxo-3,5-dihydro-1,3,4-thiadiazol-2-ylidene)phenyl]-2-phenylacetamide, as the compound to be administered for the treatment method.
-
Can a generic drug manufacturer sell a drug for treating arthritis before August 2030 if it uses a compound covered by Patent 8,809,292?
Generally, no. If the generic drug product practices the patented method of treatment as claimed in Patent 8,809,292, its sale for that indicated use would infringe the patent until its expiration.
-
How can a company assess if its new drug candidate infringes on Patent 8,809,292?
A Freedom to Operate (FTO) analysis conducted by patent counsel is necessary. This involves comparing the claims of Patent 8,809,292 with the proposed drug's active ingredient, dosage form, and intended therapeutic use.
Citations
[1] Wyeth. (2014, August 19). Method of treatment using (N-arylalkanamide derivatives) (U.S. Patent No. 8,809,292). United States Patent Office.
More… ↓
⤷ Start Trial
|
